News | November 08, 2010

First Patient Enrolled in Femoral Access/Closure Device Study

November 8, 2010 – Patient enrollment has begun in a trial looking at a new system for patients undergoing diagnostic angiography procedures through the femoral artery. The RECITAL study will observe the safety and effectiveness of the Arstasis One access system. It is expected to enroll up to 500 patients in at least seven U.S. hospitals.

Since 1959, physicians have been using the modified Seldinger technique to insert flexible catheters into a patient’s femoral artery. At the end of every such case, each patient is left with a substantial hole in his/her femoral artery, which typically takes significant effort and cath lab resources to get to stop bleeding.

Using the Arstasis One access system, physicians may create a shallow-angle needle pathway through the wall of the femoral artery. At the end of the procedure, all that is needed is approximately three to four minutes of mild, nonocclusive finger-pressure. That – combined with the patient’s femoral artery blood flow – helps collapse the shallow-angle pathway and quickly seal the site.

"We've begun performing Arstaotomy procedures routinely in our cath lab because they make femoral artery access safer for our patients, easier for me and my staff and less expensive for our hospital compared with closure devices or manual compression," said Frank Kresock, M.D., chief of interventional cardiology at La Paz Regional Medical Center in Parker, Ariz. The trial’s first patient was enrolled at the center and Kresock performed the procedure.

"The Arstasis One femoral artery access system marks the beginning of a new approach to heart catheterization," said Zoltan G. Turi, M.D., director of the vascular center at Cooper University Hospital and the national principal investigator of the study. "We hope to show that patients who participate in this study benefit from femoral artery closure that has advantages over regular manual compression. We are also interested in this technology because Arstasis-facilitated closure, unlike vascular closure devices, does not result in any foreign materials being implanted."

For more information: www.arstasis.com


Related Content

News | Cardiovascular Clinical Studies

May 31, 2024 — CareDx, a leading precision medicine company focused on the discovery, development, and commercialization ...

Home May 31, 2024
Home
News | Cardiovascular Clinical Studies

May 29, 2024 — Data was presented by AstraZeneca on AZD0780, an oral PCSK9 inhibitor which demonstrated significant LDL ...

Home May 29, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — A newly-published peer-reviewed study in the Journal of the American Heart Association, JAHA, found that ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 21, 2024 — A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging ...

Home May 21, 2024
Home
News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
Subscribe Now